Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Study Suggests Smaller Melanoma Excision Margins May Be Option for Some Patients
(Posted: 12/02/2011) - A randomized controlled trial of patients with stage IIA–C cutaneous melanoma thicker than 2-mm found that a 2-cm surgical resection margin is sufficient and is as safe for patients as a 4-cm margin in terms of overall survival, according to a report published online October 21 in The Lancet.
- Study Confirms Letrozole Prevents More Breast Cancer Recurrences than Tamoxifen
(Posted: 12/02/2011) - After a median of 8 years of follow-up from a large randomized trial, women with estrogen-receptor positive breast cancer who received 5 years of treatment with letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen.
- Long-Term Data from 20 Trials Confirm Tamoxifen’s Long-Lasting Benefit
(Posted: 11/23/2011) - In an analysis of data from participants in 20 clinical trials, women with estrogen receptor-positive breast cancer who received about 5 years of adjuvant treatment with tamoxifen had a lower risk of recurrence in the 15 years after starting treatment than women who did not receive tamoxifen.
- Chemotherapy Less Toxic to the Heart May Be Option for Some Women with HER2-Positive Breast Cancer
(Posted: 11/03/2011) - A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab may be an option for some women with HER2-positive breast cancer, according to results from the Breast Cancer International Research Group 006 (BCIRG-006) trial reported October 6, 2011, in the New England Journal of Medicine.
- Smoking Cessation Drug Proves Effective in Single-Center Trial
(Posted: 11/03/2011) - The smoking cessation drug cytisine was more effective than a placebo at helping participants abstain from smoking, according to results of a randomized controlled trial published in the September 29, 2011, issue of the New England Journal of Medicine.